Stock MOB MOBERG PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Moberg Pharma AB Stock

Equities

MOB

SE0020353928

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 03:59:51 2025-01-21 EST 		5-day change 1st Jan Change
9.653 SEK -2.35% Intraday chart for Moberg Pharma AB +3.44% -5.46%
12-18 Moberg Pharma Secures New Terbinafine Supplier for Nail Fungus Drug MT
12-18 Stockholm Bullets - Ovzon rises on big order, Fingerprint falls on new issue FW

Valuation: Moberg Pharma AB

Capitalization 462M 41.85M 40.24M 37.99M 34.02M 59.92M 3.61B 66.83M 171M 1.49B 157M 154M 6.51B P/E ratio 2024 *
-24.7x
P/E ratio 2025 * -33x
Enterprise value 183M 16.61M 15.97M 15.08M 13.5M 23.78M 1.43B 26.52M 67.88M 591M 62.28M 61M 2.59B EV / Sales 2024 *
18.3x
EV / Sales 2025 * 10.1x
Free-Float
78.15%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Moberg Pharma AB

Dynamic Chart

Latest news: Moberg Pharma AB

Moberg Pharma Secures New Terbinafine Supplier for Nail Fungus Drug 12-18 MT
Stockholm Bullets - Ovzon rises on big order, Fingerprint falls on new issue 12-18 FW
Moberg Pharma secures new terbinafine supplier for MOB-015 12-18 FW
Moberg Pharma AB Secures New Terbinafine Supplier 12-18 CI
Slight decline on the Stockholm Stock Exchange, OMXS30 index down 0.3 percent 12-11 FW
Cipher Pharmaceuticals Says Partner Moberg's Phase 3 Nail Fungus Study Did Not Meet Primary Endpoint 12-11 MT
Moberg Pharma AB - Special Call 12-11
Stockholm Bullets - Moberg Pharma plummets 12-11 FW
Confirmed: Moberg Pharma's MOB-015 did not meet primary endpoint in phase 3 study (update) 12-11 FW
Confirmed: Moberg Pharma's MOB-015 did not meet primary endpoint in phase 3 study 12-11 FW
Moberg Pharma, Bayer to Call Off Licensing Deal for Nail Fungus Treatment 12-10 MT
Moberg Pharma AB Reports Topical Terbinafine Data in the North American Phase 3 Study and Will Regains the Full Rights for MOB-015 in EU 12-10 CI
Moberg Pharma AB, Q3 2024 Earnings Call, Nov 12, 2024 11-12
More news

Last Transcript: Moberg Pharma AB

Logo Moberg Pharma AB
Moberg Pharma AB - Special Call
12-11
More transcripts

Analysts' recommendations: Moberg Pharma AB

Today's stock recommendations at a glance 24-09-16 FW
Redeye cuts motivated value for Moberg Pharma after study setback 24-09-16 FW
Redeye lowers motivated value for Moberg Pharma to SEK 19 (32) 24-09-16 FW
Redeye raises motivated value for Moberg Pharma to SEK 32 (29) 24-08-14 FW
Redeye raises motivated value for Moberg Pharma to SEK 24.5 (23) 24-05-08 FW
More recommendations

Press Releases: Moberg Pharma AB

New terbinafine supplier secured 12-18 AQ
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU 12-10 AQ
Moberg Pharma : acute;s Interim report January - September 2024 11-12 PU
Moberg Pharma's Interim report January - September 2024 11-12 AQ
Moberg Pharma : Nomination Committee appointed 11-08 PU
More press releases

Quotes and Performance

1 day-2.35%
1 week+3.44%
Current month-5.46%
1 month-8.43%
3 months-9.97%
6 months-75.18%
Current year-5.46%
More quotes

Course Extremes

1 week
8.83
Extreme 8.825
10.08
1 month
8.83
Extreme 8.825
10.84
Current year
8.83
Extreme 8.825
10.60
1 year
6.34
Extreme 6.335
40.90
3 years
6.15
Extreme 6.15
53.80
5 years
6.15
Extreme 6.15
250.00
10 years
6.15
Extreme 6.15
861.00
More quotes

Managers and Directors: Moberg Pharma AB

Director TitleAgeSince
Anna Ljung CEO
 Chief Executive Officer 45 2019-05-14
Mark Beveridge DFI
 Director of Finance/CFO 47 2014-12-31
Anders Bröijersén CTO
 Chief Tech/Sci/R&D Officer 61 2022-12-31
Manager TitleAgeSince
Nikolaj Sørensen BRD
 Director/Board Member 53 2020-12-31
Anders Lundmark BRD
 Director/Board Member 67 2022-05-15
Kerstin Valinder-Strinnholm CHM
 Chairman 65 2022-05-15
More insiders

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
MOBERG PHARMA AB Stock Moberg Pharma AB
-2.35%+3.44%-38.37%-81.22%41.85M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-4.21%-9.00%+15.45%+198.49%653B
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.50%+1.77%-9.06%-11.03%354B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+1.41%-5.77%-23.19%+76.81%341B
ABBVIE INC. Stock AbbVie Inc.
-1.23%-2.93%+4.12%+28.96%303B
MERCK & CO., INC. Stock Merck & Co., Inc.
-2.76%-3.03%-17.64%+21.26%248B
ROCHE HOLDING AG Stock Roche Holding AG
-0.41%+1.06%+7.43%-26.19%236B
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.44%+1.96%+2.34%+23.83%206B
NOVARTIS AG Stock Novartis AG
+0.25%-0.64%-5.16%+12.09%197B
PFIZER, INC. Stock Pfizer, Inc.
-0.72%-1.87%-7.00%-51.34%149B
Average -1.02%-1.64%-7.11%+19.17% 268.75B
Weighted average by Cap. -1.34%-3.59%-1.48%+59.35%
See all sector performances

Financials

2024 *2025 *
Net sales 10M 907K 872K 823K 737K 1.3M 78.16M 1.45M 3.71M 32.25M 3.4M 3.33M 141M 22M 1.99M 1.92M 1.81M 1.62M 2.86M 172M 3.19M 8.15M 70.94M 7.48M 7.33M 311M
Net income -17M -1.54M -1.48M -1.4M -1.25M -2.21M -133M -2.46M -6.3M -54.82M -5.78M -5.66M -240M -14M -1.27M -1.22M -1.15M -1.03M -1.82M -109M -2.03M -5.19M -45.14M -4.76M -4.66M -198M
Net Debt -278M -25.24M -24.27M -22.91M -20.52M -36.14M -2.18B -40.31M -103M -898M -94.67M -92.71M -3.93B -239M -21.67M -20.84M -19.67M -17.62M -31.03M -1.87B -34.6M -88.57M -771M -81.27M -79.59M -3.37B
More financial data * Estimated data

Company Profile

Logo Moberg Pharma AB
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
Employees
9
Sector
Pharmaceuticals
Calendar
2025-02-11 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
25-01-21 9.705 kr -1.82% 42,583
25-01-20 9.885 kr +3.78% 174,634
25-01-17 9.525 kr +6.78% 287,064
25-01-16 8.920 kr -1.71% 375,261
25-01-15 9.075 kr -2.37% 387,972

Delayed Quote Nasdaq Stockholm, January 21, 2025 at 03:46 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart MOBERG-PHARMA-AB More financial data
Profit revisions
estimates-change-chart MOBERG-PHARMA-AB Estimate revisions

Annual profits - Rate of surprise

quality-estimates-chart MOBERG-PHARMA-AB Company calendar
  1. Stock Market
  2. Equities
  3. MOB Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition